{"ticker": {"uuid": "430841ce-b2bb-4e1c-893b-9c1fecd1b488", "symbol": "IMUX", "name": "Immunic Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "abrdn discloses 6.05% Immunic (IMUX) stake held for clients", "summary": "abrdn Group plc and its subsidiary abrdn Inc. have disclosed a beneficial ownership of 824,393 shares of Immunic, Inc. (IMUX) common stock, representing 6.05% of the outstanding class. This ownership is held on behalf of their clients, with shared voting and dispositive power. Th", "url": "https://www.stocktitan.net/sec-filings/IMUX/schedule-13g-a-immunic-inc-amended-passive-investment-disclosure-4cf599ea3a9c.html", "source_name": "Stock Titan", "published_at": "2026-07-16T10:11:28", "published_display": "16 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic posts updated corporate presentation under Regulation FD", "summary": "Immunic (IMUX) has made an updated investor presentation available on its website, filed as Exhibit 99.1 to its Form 8-K on July 14, 2026. This presentation, furnished under Regulation FD, includes forward-looking statements regarding the company's development programs, clinical ", "url": "https://www.tradingview.com/news/tradingview:1f4ab76ebc20a:0-immunic-posts-updated-corporate-presentation-under-regulation-fd/", "source_name": "TradingView", "published_at": "2026-07-14T11:41:14", "published_display": "14 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (NASDAQ: IMUX) releases new presentation on pipeline and plans", "summary": "Immunic, Inc. (NASDAQ: IMUX) released an updated corporate presentation on July 14, 2026, accessible on its website and filed as Exhibit 99.1. This presentation includes forward-looking statements regarding the company's strategy, cash runway, clinical development for vidofludimu", "url": "https://www.stocktitan.net/sec-filings/IMUX/8-k-immunic-inc-reports-material-event-62cc6b889858.html", "source_name": "Stock Titan", "published_at": "2026-07-14T11:41:14", "published_display": "14 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immunic (IMUX) Short Interest & Short Float | Updated Jul 2026", "summary": "This article provides an updated overview of Immunic (IMUX) short interest and related metrics as of June 30, 2026. Immunic had 1.59 million shares sold short, representing 12.33% of its public float, marking a 2.65% decrease from the previous report. The short interest ratio is ", "url": "https://www.marketbeat.com/stocks/NASDAQ/IMUX/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-11T06:44:12", "published_display": "11 Jul 2026 06:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic stock trades steadily as pipeline and Nasdaq listing shape investor focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNTFlMclZaTTgzWm1pbFU2Z1JfLWtiVGFGVkhEZU5VZFY4WGRNc0dtVm5DQ3VXeW56WWtHaVAtWmdxOXQ5Y1BpZHhqakg0NVdfeloxamdHbHBTX1RZMmNRWGtvMU0yMGFhajVkQTBOVFg0LTlWRjRhZ0xKV3l0OFRCVnQxQWZVbHFBWFNuandJUGtUWTlnM19OQnhJVzdwUGliZlBlUFczTjdyTFhSMExXcllJUW5OYkhieWVVaEdtczBLdWM?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-09T18:57:22+00:00", "published_display": "09 Jul 2026 18:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic to Participate in Investor Conferences in July", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOeUZrMFhPc2tfeEZEeXA0ZVBBUF80R2kwOFNLTTUyTlpWeWJ1VE1DRkVEMGxQZ1A5eF9NQzZKYnJOVUZIMkxYVFA5Y2hMWGQwc0FmMHNaRmVIWjFvaVNtVzZIMjdaZmFmXzJhejZQaU5DLV9kQXFmN1pZN0R2NWVzVzlIaGd5ZHV6eGNGSGFsTXF2ekdFd05GZXdBQzZWbXdUd21ZMnJtYmlINTA3bHJz?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Immunic Inc For: 7 July By Investing.com", "summary": "This article reports on a Form 4 filing for Immunic Inc. on July 7, 2026. Form 4 filings are used to declare changes in beneficial ownership of securities by a company's directors, officers, or beneficial owners. The content includes Immunic Inc.'s stock symbol (IMUX) and its cur", "url": "https://ng.investing.com/news/stock-market-news/form-4-immunic-inc-for-7-july-93CH-2589647", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T05:09:57", "published_display": "08 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic Names CEO Erik Lundgren to Board", "summary": "Immunic announced that its CEO, Erik Lundgren, has been appointed as a Class II director to its Board, effective July 5, 2026. This appointment follows the resignation of director Tamar Howson, who retired on June 29, 2026, with no disagreements cited. Lundgren will not receive a", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IMUX-Q/pressreleases/3171981/immunic-names-ceo-erik-lundgren-to-board/", "source_name": "The Globe and Mail", "published_at": "2026-07-07T20:41:01", "published_display": "07 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUNIC (IMUX) director Barclay Phillips awarded 25,370 stock options as equity pay", "summary": "IMMUNIC, INC. director Barclay A. Phillips was awarded 25,370 stock options as equity compensation. These options have an exercise price of $14.80 per share, expire on July 5, 2036, and will vest in monthly increments over one year. Following this grant, Phillips directly holds 2", "url": "https://www.stocktitan.net/sec-filings/IMUX/form-4-immunic-inc-insider-trading-activity-0634897d93a5.html", "source_name": "Stock Titan", "published_at": "2026-07-07T19:41:01", "published_display": "07 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUNIC (IMUX) director receives 25,370 stock options at $14.80 strike price", "summary": "IMMUNIC (IMUX) director Joerg Neermann was granted 25,370 stock options with an exercise price of $14.80 per share. These options will vest monthly over one year from the grant date of July 5, 2026, and will expire on July 5, 2036. This transaction was reported in an SEC Form 4 f", "url": "https://www.stocktitan.net/sec-filings/IMUX/form-4-immunic-inc-insider-trading-activity-54c4163d8f64.html", "source_name": "Stock Titan", "published_at": "2026-07-07T19:39:52", "published_display": "07 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic director granted options for 25,370 shares | IMUX Insider Trading", "summary": "Immunic, Inc. director Richard Alan Rudick was granted stock options for 25,370 shares as equity compensation. The options have an exercise price of $14.80 per share, vest monthly over one year, and expire on July 5, 2036. Following this grant, Rudick directly holds 25,370 deriva", "url": "https://www.stocktitan.net/sec-filings/IMUX/form-4-immunic-inc-insider-trading-activity-a9c027024b3b.html", "source_name": "Stock Titan", "published_at": "2026-07-07T19:39:52", "published_display": "07 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) director Jon Congleton granted 25,370 stock options at $14.80", "summary": "Immunic, Inc. director Jon Congleton was granted 25,370 stock options at an exercise price of $14.80 per share, with the options vesting monthly over one year and expiring on July 5, 2036. This transaction, categorized as a grant/award acquisition, was reported on a Form 4 filing", "url": "https://www.stocktitan.net/sec-filings/IMUX/form-4-immunic-inc-insider-trading-activity-e85e4b1313a2.html", "source_name": "Stock Titan", "published_at": "2026-07-07T19:39:52", "published_display": "07 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) CEO Erik Lundgren appointed to Board as Tamar Howson retires", "summary": "Immunic, Inc. announced a change to its Board of Directors following the retirement of Tamar Howson. She resigned from the Board and its Compensation Committee on June 29, 2026. Subsequently, on July 5, 2026, the Board appointed CEO Erik Lundgren as a Class II director to serve u", "url": "https://www.stocktitan.net/sec-filings/IMUX/8-k-immunic-inc-reports-material-event-10d0b87a916c.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:10:49", "published_display": "06 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUX - Immunic Inc Options", "summary": "This Finviz page provides a detailed financial overview of Immunic Inc (IMUX), including its last closing price, market capitalization, key financial ratios, earnings per share, and stock performance metrics. It lists crucial data such as insider and institutional ownership, shor", "url": "https://finviz.com/quote?t=IMUX&ty=oc&ta=1&p=d&ov=chain_strike&s=15", "source_name": "Finviz", "published_at": "2026-07-06T18:10:49", "published_display": "06 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUX - Immunic Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Immunic Inc (IMUX). It includes various financial metrics, stock performance, insider and institutional ownership, analyst recommendations, and key valuation ratios. The data indicates recent stock ", "url": "https://finviz.com/stock?t=IMUX&ty=lf&ta=0&p=d&page=11", "source_name": "Finviz", "published_at": "2026-07-03T16:12:09", "published_display": "03 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUX SEC Filings - Immunic Inc 10-K, 10-Q, 8-K Forms", "summary": "This article provides details of recent SEC filings for Immunic Inc. (IMUX), a biotechnology company. It highlights several insider stock option grants to directors and executives on June 29, 2026, including details on the number of shares, exercise prices, vesting schedules, and", "url": "https://www.stocktitan.net/sec-filings/IMUX/", "source_name": "Stock Titan", "published_at": "2026-06-30T14:40:25", "published_display": "30 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Immunic Inc For: 29 June By Investing.com", "summary": "This article provides a Form 4 filing for Immunic Inc. as of June 29, referencing the stock ticker IMUX. It is a brief announcement indicating the availability of a regulatory filing related to insider transactions for the company. The article includes various financial market da", "url": "https://au.investing.com/news/stock-market-news/form-4-immunic-inc-for-29-june-93CH-4509865", "source_name": "Investing.com Australia", "published_at": "2026-06-30T11:40:09", "published_display": "30 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) director receives 25,370 fully vested options", "summary": "Immunic, Inc. director Simona Skerjanec was granted 25,370 stock options with an exercise price of $10.90 per share, fully vested as of March 27, 2026. The approval of these options was contingent on stockholder approval of an amendment to the company's 2019 Omnibus Equity Incent", "url": "https://www.stocktitan.net/sec-filings/IMUX/form-4-immunic-inc-insider-trading-activity-b2d0e42c2b1d.html", "source_name": "Stock Titan", "published_at": "2026-06-30T01:40:09", "published_display": "30 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) director Neermann receives fully vested options on 25,370 shares", "summary": "Immunic (IMUX) director Joerg Neermann was granted 25,370 stock options with an exercise price of $10.90 per share, fully vested as of March 27, 2026. This grant was conditional on stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan, which occurred on J", "url": "https://www.stocktitan.net/sec-filings/IMUX/form-4-immunic-inc-insider-trading-activity-bf701995a2ad.html", "source_name": "Stock Titan", "published_at": "2026-06-30T01:40:09", "published_display": "30 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) investors boost equity pool and reelect directors at 2026 meeting", "summary": "Immunic, Inc. stockholders approved an amendment to the 2019 Omnibus Equity Incentive Plan, increasing authorized shares for issuance by 6,000,000 to a total of 8,644,887 common shares. This expansion provides more equity for employee and director awards. Additionally, three Clas", "url": "https://www.stocktitan.net/sec-filings/IMUX/8-k-immunic-inc-reports-material-event-fe0110321dbf.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:39:47", "published_display": "29 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic, Inc.(NasdaqCM: IMUX) added to Russell 3000E Value Benchmark", "summary": "Immunic, Inc. (NasdaqCM: IMUX), a biotechnology company specializing in oral immunology therapies, has been added to the Russell 3000E Value Benchmark. The article highlights Immunic's clinical pipeline, including its IMU-838 program in Phase III development for multiple sclerosi", "url": "https://www.marketscreener.com/news/immunic-inc-nasdaqcm-imux-added-to-russell-3000e-value-benchmark-ce7f5fddda8af225", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T14:13:14", "published_display": "29 Jun 2026 14:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) director receives grant of 25,370 fully vested options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPeUg5VUg5Qmc0Q0VKYk1kWktjSndvQklhRGlzNEswYTFtdDdHdUFZdjYwZHQ2S0ZkNEQ3QTRKbUhyNndBdy1xX2h5Q09sRU5sNmR2STJONnF4UUh2ODl2b3RLSWhaT2N3Ymd6Y0FJQkFDVFQ5c0VmX3dTMW4zdk5TVlREdUtpQ29yVldMUkpfZFI2VnZJaDJqWlYwTHJySTQ4eXgwQ1hveHo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUNIC (IMUX) director receives 445,000 stock options at $11.60 exercise price", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOMnYzeEk1bF9aZ04zcFd2Q3d3RzF2WVdlMFFaQXRXQ0VKRURZejlOM0d5WWFrZmtzRVJsZHU1RFdjbkdtZXNvVUM3LXBlM3VzUFRxb3ItczFtVE9SODlqbWo2X3ROTzBHSDZGVllVVWFNNTZYNGhUaXo2VTdqUUQ1MGd1eHJmU2VqaG5tMHhVTEctN0twcl9BMUJITTRCYTVZZlQxOFBjNDM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (NASDAQ: IMUX) director receives 25,370 stock options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPRWN5aTVOeHU4QzhQcmVZbU9JUDhQTjY5UXJMaVdDQ0FybUZnUjVXOGJJQWMtQXpxUHo4VndnY1U0bFUyaEl5cV9haTY4OVVwT051NnZmS2phcm1oV2pfMThmYW5xWmo1NGwwT2ZwUkw3aDJ0bDBjczRCZDVxSHRPa0NNVWctbGNmNDg4bXpDLTNFS2RtX3hzOElNYXVIR2lnb1RPdi1hYXA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUNIC (IMUX) director Barclay Phillips receives 25,370 fully vested stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQM3VnNGJmUzQ4am51OHdDTVo2eUZRaG1JUmwyQ1ItdURRU2VFWjVYRlpxU3dhMy1mNlpWMGdHcTd4c05oZV9DNWxQZjBuTjYxekhkSFo1NHZsUk5JZm5JT29zLXRNeTFRSFQwdVRTVlducHVXc3JnSFdaRlV2b25JUFlsM0JKdnNpbHE0Vl9yWkVqMVM5X3djWHNONm1zdlNfQXdIT2ZvcGQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUNIC (IMUX) President and COO receives 253,000-share stock option grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZXNwbW40UWRuQk4zNVNCQlhYUHVpNU1WejV4YWpVcHdpS0ZVZGl6M0dwZ3BEeHlScE9JV3ZHUWFZVGhxOTM3dmM3a1pZU0ZfbkRGNXpBaXBUNUVod1o1WUN3UkFEMFRqRE1RekNOWWVueGpFT2tPX29jZDBXbWU3LUIyMTBTdkllalV4TlhDNkFTaExWT1FYM1hNdXZPRTNyN2JBMWd0bmI?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Immunic, Inc. \u2013 NASDAQ:IMUX", "summary": "This article displays the \"Price to earnings forward\" financial metric for Immunic, Inc. (NASDAQ: IMUX). The content indicates \"No trades\" and \"Market closed,\" suggesting a lack of recent trading activity or data points for this specific financial ratio. The page provides a gener", "url": "https://www.tradingview.com/symbols/NASDAQ-IMUX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:39:20", "published_display": "27 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Immunic, Inc. \u2013 BOATS:IMUX", "summary": "This article provides financial information for Immunic, Inc. (IMUX), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed with no trades recorded at the time of publication. The content also mentions the various data providers for", "url": "https://www.tradingview.com/symbols/BOATS-IMUX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:40:51", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic tests Nurr1 to push beyond MS\u2019s inflammation ceiling", "summary": "Immunic Inc. is testing vidofludimus calcium, a Phase III candidate for multiple sclerosis, which combines DHODH inhibition with Nurr1 activation. This approach aims to pair targeted immune modulation with direct neuroprotective effects to slow MS progression, addressing the limi", "url": "https://www.biocentury.com/article/659787/immunic-tests-nurr1-to-push-beyond-ms-s-inflammation-ceiling", "source_name": "BioCentury", "published_at": "2026-06-27T00:40:51", "published_display": "27 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Immunic, Inc. \u2013 MUN:10V", "summary": "This article provides a financial snippet for Immunic, Inc. (MUN:10V), specifically focusing on its \"Price to book forward\" metric. The content indicates that the market for this stock is currently closed with no trades. It also lists various data providers for the financial info", "url": "https://www.tradingview.com/symbols/MUN-10V/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:39:52", "published_display": "25 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Immunic, Inc. \u2013 MUN:10V", "summary": "The article discusses the enterprise value to revenue for Immunic, Inc. (MUN:10V), traded on the Munich Stock Exchange. It appears to be a financial data snippet from a trading platform, indicating the market was closed with no trades.", "url": "https://www.tradingview.com/symbols/MUN-10V/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:11:22", "published_display": "25 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Immunic, Inc. \u2013 NASDAQ:IMUX", "summary": "This article displays the \"Enterprise value to EBITDA forward\" for Immunic, Inc. (NASDAQ:IMUX) on TradingView. It appears to be a financial data point without additional analytical text, found within the financial overview section of the company's profile on the platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-IMUX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T09:09:56", "published_display": "25 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eqs-News: Immunic to Present Additional Phase", "summary": "This article announces that Immunic will present additional Phase data, as indicated by the title \"Eqs-News: Immunic to Present Additional Phase\". However, the full content of the document is missing, making it impossible to provide further details on what data will be presented ", "url": "https://www.moomoo.com/news/flash/22557834/eqs-news-immunic-to-present-additional-phase-2-calliper-trial", "source_name": "Moomoo", "published_at": "2026-06-24T23:39:52", "published_display": "24 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Immunic, Inc. \u2013 NASDAQ:IMUX", "summary": "This article displays financial data for Immunic, Inc. (IMUX) on TradingView, specifically focusing on its enterprise value to EBIT forward ratio. The content seems to be a snapshot from a financial data platform, providing this metric for the pharmaceutical company.", "url": "https://www.tradingview.com/symbols/NASDAQ-IMUX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T19:41:35", "published_display": "24 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic Inc (FRA:10V) Stock Price & 30 Year Financial Data", "summary": "This article provides comprehensive 30-year financial data for Immunic Inc (FRA:10V), detailing growth rates for revenue, EPS, EBIT, EBITDA, and Free Cash Flow, along with price performance. It also includes key financial metrics such as Market Cap, Enterprise Value, PE Ratio, PB", "url": "https://www.gurufocus.com/stock/FRA:10V/financials", "source_name": "GuruFocus", "published_at": "2026-06-24T13:09:56", "published_display": "24 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic to Participate in Investor, Industry and Scientific Conferences in June", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immunic-participate-investor-industry-scientific-103000653.html", "source_name": "PR Newswire", "published_at": "2026-06-10T10:30:00+00:00", "published_display": "10 Jun 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic presents new vidofludimus calcium data at multiple sclerosis conference", "summary": "", "url": "https://finance.yahoo.com/m/1a380b41-3f0a-3ff9-8057-2042f00c4f69/immunic-presents-new.html", "source_name": "Proactive", "published_at": "2026-05-28T14:29:00+00:00", "published_display": "28 May 2026 14:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwJBVV95cUxOMmppSS1sU3dLa1hyTEx5TUVBVEhmcmprME9Ca1REdVhQanlGcmhIUjFWQnlIWTQ2LXUyRUx2aWUxX3g0TzQ2MlMwUWV4QVRQV1RmdzBfRXF6R0lqUl9ZRHlURUpReVIyeXlLUkxDUExqUU05dUdKTlZlSHd6cDd0Tk11ejIxaW03TXhhMWhEX3VsZS1kUWt6S0dWbUF2OWtIRVpNQkFmbjJUejhqTHNJeG1LbUp0Qk5VUTJzR1BNaEVYSFJrblRhUll1SHJPSE5KdkR6TVFlS1Q1eDFYT05zdlRJbnpPbFk2NkozUUNhT3dtaXJLM3J2LUlKTk1CVnlFY2taZ3VvWi1EYjA5NHdkcU1Lc1ktb0NKWmVoOWZIYkxwWHhrWWFWdHhNZ0hzNFc5ZnFibU04WUNPeVVmY2Z4eUJibFJ2RmI5dUNWS1AwMA?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials", "summary": "", "url": "https://finance.yahoo.com/m/13af05f7-1a6c-3a84-b5e0-555bd7424b81/immunic-names-erik-lundgren.html", "source_name": "Proactive", "published_at": "2026-05-27T13:06:00+00:00", "published_display": "27 May 2026 13:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/exclusive-immunic-appoints-former-genentech-101745260.html", "source_name": "Benzinga", "published_at": "2026-05-27T10:17:45+00:00", "published_display": "27 May 2026 10:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOTGR3N2c2N2xKdFd2Y3g2MXZyV042SUIydWVDdS15aDRSN3BaWUFEQmU2YWdXdVpkTVVfbUFrdldFd1hYblQ5SjZqc0lXTlZ6eDhTaVhOeGxMUF9GVWd6X1ZKbVBKV1djNThJN3psQV9weHd6YXU2QXpmRDAtZ3dldERtRFVsNHhiM1V3UVJPckIwazRVemJUUVRNTHZoY1hmOW54UWdaUlRDWDVKazhaRUp2M3dfWFh5MmVONkFSQ184X3JCaV9WREpVRHlhU0prb2Vidlk4NFRieV9IOTZ1UmloelozSDFrSTM4?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout", "summary": "", "url": "https://finance.yahoo.com/m/6c03c95a-4946-3c70-ae8e-860ac7dd3477/immunic-appoints-biogen%2C.html", "source_name": "Proactive", "published_at": "2026-05-19T13:33:00+00:00", "published_display": "19 May 2026 13:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immunic-appoints-seasoned-biopharmaceutical-executive-103000434.html", "source_name": "PR Newswire", "published_at": "2026-05-19T10:30:00+00:00", "published_display": "19 May 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunic-nasdaq-imux-good-position-143141130.html", "source_name": "Simply Wall St.", "published_at": "2026-05-17T14:31:41+00:00", "published_display": "17 May 2026 14:31", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immunic stock (US45256V1061): Q1 earnings and Phase 3 trial preparations", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOSFhHNE56ZVEzVjB4bUZ2NW8ycXFJVjZ2eUh5d3ZMM3BJaGJlWTFrbjItUndWaUZoVjBHb2tWZmxlbXlyaC1fN0lkZXFLNXhiSmJVanhyRHo5aDVuczJKNkdPd1otc3hGYTJ6WUt0eUVLNkVIaUFHOXZxVXpEa0tfcDB3YVZlNzIzQWlPOGxGQ2cteDlsMWc1SjJSVUhabnJVakFnb0VPQU9oYVpDeVg2SXU2QWN2STVxZXVsb0NjeDY3UFVpRjVB?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQT19UUTgzYU1fUmdzSDNmaVgwZVFKbWpWa3ZUdnFrWGdNcjhqcUFnWVJyM19QNDFvTGFRcS1QTlNhMUVWVWhDa0tSTG9PN0dYYVVWSnNBYWpOY3FfWlQ5bWNhNENMVDZVc1VJVk52SzYzOG1jQTBpWDZaeWhsTngwYW1oVGNYSEY4YzhQWlVscVFad2VvdkJRejZkVGZyVnpqR1FsYld4N0c3V0xwUjJIblRDWUJ4MkxUeDJoR1ViS1BvQlVhaWZJSkxRQXo2eHF1SktOeW5ROA?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) Q1 2026 Earnings: EPS N/A, Revenue N/A -- Is the", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQUWtCS0xxcExaM2wxRmJQOGtMMkR3S1EzMTdMdlBpaDUwOUQycFFlWnA3NldzQmVZcnQ4U3hxQUxONTdNVDQ4c2tEWEstS1VQcl9iSDV3bHNONVFhbTBkcXAyUEZ2cWV5bDl4Z1cxaHVtM2Vjd0JVd2Y0N1pKcWEtV1B5NUdISWx4Y1NpQmNYZmZOUzFRWnBOREM3c09zdXVRNUlKUXpDTUFJaFhkSTdZMVhiV2pyUWNNZEVZam0xeFlaaWhGUTZwaHlWaXZSNnJkS1JQOA?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic Releases Q1 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE1rZ3dkR2d2a2VNX3NtT19OTUJLOHRmUWhINHRyazdpdFZlVzRfMjNSalJFU1RoVTVxejZiM3g2YkVQWTE3TGhybUdWVzJnNnpWdmV1d3U1YkpMWE9KNFNYNkVIVUgyak5CdVBYNjRGdmVhM25ncy1XQ1RGVWjSAXxBVV95cUxNa2d3ZEdndmtlTV9zbU9fTk1CSzh0ZlFoSDR0cms3aXRWZVc0XzIzUmpSRVNUaFU1cXo2YjN4NmJFUFkxN0xocm1HVlcyZzZ6VnZldXd1NWJKTFhPSjRTWDZFSFVIMmpOQnVQWDY0RnZlYTNuZ3MtV0NURlVo?oc=5", "source_name": "AlphaStreet", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immunic, Inc. Announces 1-for-10 Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQSTFxLXBTOWx0eGE0b3NKUzVfQXlIYjVSMWN1b2RNVGpRYWYxWXBUU2FsZW5BemRyc0xWYi1HYXpMVURHSm42TUpRdGNOZTBHUTBOMXY5c2JPYS1zeEM4RHlvY0t6ckR3QnhMRFc4LXVCbkZyYW1NYkhKS1Mwc1JzdnJBMlNKTC1zUHY2a0l0MFQ1UElfckFHUVFfYzNWUzdXb0pzd1RmZw?oc=5", "source_name": "TradingView", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immunic shareholders approve 1-for-10 reverse stock split, effective April 27", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNYWhjeDczcEtkTHlYdGdXVUdiRmQtUll2ZmdvbkVuc293LXJ0QlRxMWRweXkyaE4zcWs0ZlZJSXdPNDRHZ1ZPYVkxMTU5Z2VpU3VwaUpkNW5BVjJPVUlHRElRZklKQWZRSGNKZzVjTnczYlRpNjJsTm95Um9qMU1HWHdZMGotdUcwMjFrTExXMkdhTnVmdmk0MG1uMWRYN1JnR0ZWSzY2TUVOak41aS1NLUtYS3E2bGF1eTdWZ2UyU0w5WkloMDFnRk9n?oc=5", "source_name": "Investing.com", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Should Extended European Patent Protection for Vidofludimus Calcium Reshape Immunic\u2019s (IMUX) Long-Term Value Proposition?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxONTl5ZGtRMldWQUNNQW1obHZrMkFEV3R4aExOUVVUd1QtLTdIay0tUllRdURMdGc0a1dNOWVEcUU2SFJMMncxOTBIeFZTcWRqbkYyUW9lU05aUjdBaDQxVDI2Sk5mYWxVdGo0dmRMek92UDlVU3NXRS1fbDhTdEltbTlUQ21yWnljSkpqOXZEZUJsZk9qMlN4S1RmU01NYkRzZExtQTQ2TU1MbmtkUEZPQmhabEZHcXZYSUVLRXZYMXF4WlFDZEhySXI5NV8wWkNGZExtZ1hvRdIB3AFBVV95cUxNY0tiVzVvWnJ5WkF4eDBFVnd3UTBCTnVlVFlLRDFBZUhON29nOEhTcmt6WEVSSldGU3VzMzJyTXhPTUZHQnJrUUl6a3UyLWUwV0xhRmhEVXFuMHloWlRFZnNwNGJ1bHlTWVgxVnVIbGo0NHdrZGVIeG81THRsb2RGQXl3TjdQclExSW90RE5mWk5Tdl9wOUdCTF9VaXRtdTB1WEFWNWZYUUc5cTNBdmxsX0NxY29mT3lCWFczYkYxcUVMQXUyVEZlbFNIblFxOVJwbXVKcTVrVllpZ1hq?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-14T07:00:00+00:00", "published_display": "14 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "abrdn discloses 6.05% Immunic (IMUX) stake held for clients", "summary": "abrdn Group plc and its subsidiary abrdn Inc. have disclosed a beneficial ownership of 824,393 shares of Immunic, Inc. (IMUX) common stock, representing 6.05% of the outstanding class. This ownership is held on behalf of their clients, with shared voting and dispositive power. Th", "url": "https://www.stocktitan.net/sec-filings/IMUX/schedule-13g-a-immunic-inc-amended-passive-investment-disclosure-4cf599ea3a9c.html", "source_name": "Stock Titan", "published_at": "2026-07-16T10:11:28", "published_display": "16 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic posts updated corporate presentation under Regulation FD", "summary": "Immunic (IMUX) has made an updated investor presentation available on its website, filed as Exhibit 99.1 to its Form 8-K on July 14, 2026. This presentation, furnished under Regulation FD, includes forward-looking statements regarding the company's development programs, clinical ", "url": "https://www.tradingview.com/news/tradingview:1f4ab76ebc20a:0-immunic-posts-updated-corporate-presentation-under-regulation-fd/", "source_name": "TradingView", "published_at": "2026-07-14T11:41:14", "published_display": "14 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (NASDAQ: IMUX) releases new presentation on pipeline and plans", "summary": "Immunic, Inc. (NASDAQ: IMUX) released an updated corporate presentation on July 14, 2026, accessible on its website and filed as Exhibit 99.1. This presentation includes forward-looking statements regarding the company's strategy, cash runway, clinical development for vidofludimu", "url": "https://www.stocktitan.net/sec-filings/IMUX/8-k-immunic-inc-reports-material-event-62cc6b889858.html", "source_name": "Stock Titan", "published_at": "2026-07-14T11:41:14", "published_display": "14 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) Short Interest & Short Float | Updated Jul 2026", "summary": "This article provides an updated overview of Immunic (IMUX) short interest and related metrics as of June 30, 2026. Immunic had 1.59 million shares sold short, representing 12.33% of its public float, marking a 2.65% decrease from the previous report. The short interest ratio is ", "url": "https://www.marketbeat.com/stocks/NASDAQ/IMUX/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-11T06:44:12", "published_display": "11 Jul 2026 06:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic stock trades steadily as pipeline and Nasdaq listing shape investor focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNTFlMclZaTTgzWm1pbFU2Z1JfLWtiVGFGVkhEZU5VZFY4WGRNc0dtVm5DQ3VXeW56WWtHaVAtWmdxOXQ5Y1BpZHhqakg0NVdfeloxamdHbHBTX1RZMmNRWGtvMU0yMGFhajVkQTBOVFg0LTlWRjRhZ0xKV3l0OFRCVnQxQWZVbHFBWFNuandJUGtUWTlnM19OQnhJVzdwUGliZlBlUFczTjdyTFhSMExXcllJUW5OYkhieWVVaEdtczBLdWM?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-09T18:57:22+00:00", "published_display": "09 Jul 2026 18:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic to Participate in Investor Conferences in July", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOeUZrMFhPc2tfeEZEeXA0ZVBBUF80R2kwOFNLTTUyTlpWeWJ1VE1DRkVEMGxQZ1A5eF9NQzZKYnJOVUZIMkxYVFA5Y2hMWGQwc0FmMHNaRmVIWjFvaVNtVzZIMjdaZmFmXzJhejZQaU5DLV9kQXFmN1pZN0R2NWVzVzlIaGd5ZHV6eGNGSGFsTXF2ekdFd05GZXdBQzZWbXdUd21ZMnJtYmlINTA3bHJz?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Immunic Inc For: 7 July By Investing.com", "summary": "This article reports on a Form 4 filing for Immunic Inc. on July 7, 2026. Form 4 filings are used to declare changes in beneficial ownership of securities by a company's directors, officers, or beneficial owners. The content includes Immunic Inc.'s stock symbol (IMUX) and its cur", "url": "https://ng.investing.com/news/stock-market-news/form-4-immunic-inc-for-7-july-93CH-2589647", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T05:09:57", "published_display": "08 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic Names CEO Erik Lundgren to Board", "summary": "Immunic announced that its CEO, Erik Lundgren, has been appointed as a Class II director to its Board, effective July 5, 2026. This appointment follows the resignation of director Tamar Howson, who retired on June 29, 2026, with no disagreements cited. Lundgren will not receive a", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IMUX-Q/pressreleases/3171981/immunic-names-ceo-erik-lundgren-to-board/", "source_name": "The Globe and Mail", "published_at": "2026-07-07T20:41:01", "published_display": "07 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUNIC (IMUX) director Barclay Phillips awarded 25,370 stock options as equity pay", "summary": "IMMUNIC, INC. director Barclay A. Phillips was awarded 25,370 stock options as equity compensation. These options have an exercise price of $14.80 per share, expire on July 5, 2036, and will vest in monthly increments over one year. Following this grant, Phillips directly holds 2", "url": "https://www.stocktitan.net/sec-filings/IMUX/form-4-immunic-inc-insider-trading-activity-0634897d93a5.html", "source_name": "Stock Titan", "published_at": "2026-07-07T19:41:01", "published_display": "07 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUNIC (IMUX) director receives 25,370 stock options at $14.80 strike price", "summary": "IMMUNIC (IMUX) director Joerg Neermann was granted 25,370 stock options with an exercise price of $14.80 per share. These options will vest monthly over one year from the grant date of July 5, 2026, and will expire on July 5, 2036. This transaction was reported in an SEC Form 4 f", "url": "https://www.stocktitan.net/sec-filings/IMUX/form-4-immunic-inc-insider-trading-activity-54c4163d8f64.html", "source_name": "Stock Titan", "published_at": "2026-07-07T19:39:52", "published_display": "07 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic director granted options for 25,370 shares | IMUX Insider Trading", "summary": "Immunic, Inc. director Richard Alan Rudick was granted stock options for 25,370 shares as equity compensation. The options have an exercise price of $14.80 per share, vest monthly over one year, and expire on July 5, 2036. Following this grant, Rudick directly holds 25,370 deriva", "url": "https://www.stocktitan.net/sec-filings/IMUX/form-4-immunic-inc-insider-trading-activity-a9c027024b3b.html", "source_name": "Stock Titan", "published_at": "2026-07-07T19:39:52", "published_display": "07 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) director Jon Congleton granted 25,370 stock options at $14.80", "summary": "Immunic, Inc. director Jon Congleton was granted 25,370 stock options at an exercise price of $14.80 per share, with the options vesting monthly over one year and expiring on July 5, 2036. This transaction, categorized as a grant/award acquisition, was reported on a Form 4 filing", "url": "https://www.stocktitan.net/sec-filings/IMUX/form-4-immunic-inc-insider-trading-activity-e85e4b1313a2.html", "source_name": "Stock Titan", "published_at": "2026-07-07T19:39:52", "published_display": "07 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) CEO Erik Lundgren appointed to Board as Tamar Howson retires", "summary": "Immunic, Inc. announced a change to its Board of Directors following the retirement of Tamar Howson. She resigned from the Board and its Compensation Committee on June 29, 2026. Subsequently, on July 5, 2026, the Board appointed CEO Erik Lundgren as a Class II director to serve u", "url": "https://www.stocktitan.net/sec-filings/IMUX/8-k-immunic-inc-reports-material-event-10d0b87a916c.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:10:49", "published_display": "06 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUX - Immunic Inc Options", "summary": "This Finviz page provides a detailed financial overview of Immunic Inc (IMUX), including its last closing price, market capitalization, key financial ratios, earnings per share, and stock performance metrics. It lists crucial data such as insider and institutional ownership, shor", "url": "https://finviz.com/quote?t=IMUX&ty=oc&ta=1&p=d&ov=chain_strike&s=15", "source_name": "Finviz", "published_at": "2026-07-06T18:10:49", "published_display": "06 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUX - Immunic Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Immunic Inc (IMUX). It includes various financial metrics, stock performance, insider and institutional ownership, analyst recommendations, and key valuation ratios. The data indicates recent stock ", "url": "https://finviz.com/stock?t=IMUX&ty=lf&ta=0&p=d&page=11", "source_name": "Finviz", "published_at": "2026-07-03T16:12:09", "published_display": "03 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMUX SEC Filings - Immunic Inc 10-K, 10-Q, 8-K Forms", "summary": "This article provides details of recent SEC filings for Immunic Inc. (IMUX), a biotechnology company. It highlights several insider stock option grants to directors and executives on June 29, 2026, including details on the number of shares, exercise prices, vesting schedules, and", "url": "https://www.stocktitan.net/sec-filings/IMUX/", "source_name": "Stock Titan", "published_at": "2026-06-30T14:40:25", "published_display": "30 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Immunic Inc For: 29 June By Investing.com", "summary": "This article provides a Form 4 filing for Immunic Inc. as of June 29, referencing the stock ticker IMUX. It is a brief announcement indicating the availability of a regulatory filing related to insider transactions for the company. The article includes various financial market da", "url": "https://au.investing.com/news/stock-market-news/form-4-immunic-inc-for-29-june-93CH-4509865", "source_name": "Investing.com Australia", "published_at": "2026-06-30T11:40:09", "published_display": "30 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) director receives 25,370 fully vested options", "summary": "Immunic, Inc. director Simona Skerjanec was granted 25,370 stock options with an exercise price of $10.90 per share, fully vested as of March 27, 2026. The approval of these options was contingent on stockholder approval of an amendment to the company's 2019 Omnibus Equity Incent", "url": "https://www.stocktitan.net/sec-filings/IMUX/form-4-immunic-inc-insider-trading-activity-b2d0e42c2b1d.html", "source_name": "Stock Titan", "published_at": "2026-06-30T01:40:09", "published_display": "30 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) director Neermann receives fully vested options on 25,370 shares", "summary": "Immunic (IMUX) director Joerg Neermann was granted 25,370 stock options with an exercise price of $10.90 per share, fully vested as of March 27, 2026. This grant was conditional on stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan, which occurred on J", "url": "https://www.stocktitan.net/sec-filings/IMUX/form-4-immunic-inc-insider-trading-activity-bf701995a2ad.html", "source_name": "Stock Titan", "published_at": "2026-06-30T01:40:09", "published_display": "30 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) investors boost equity pool and reelect directors at 2026 meeting", "summary": "Immunic, Inc. stockholders approved an amendment to the 2019 Omnibus Equity Incentive Plan, increasing authorized shares for issuance by 6,000,000 to a total of 8,644,887 common shares. This expansion provides more equity for employee and director awards. Additionally, three Clas", "url": "https://www.stocktitan.net/sec-filings/IMUX/8-k-immunic-inc-reports-material-event-fe0110321dbf.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:39:47", "published_display": "29 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic, Inc.(NasdaqCM: IMUX) added to Russell 3000E Value Benchmark", "summary": "Immunic, Inc. (NasdaqCM: IMUX), a biotechnology company specializing in oral immunology therapies, has been added to the Russell 3000E Value Benchmark. The article highlights Immunic's clinical pipeline, including its IMU-838 program in Phase III development for multiple sclerosi", "url": "https://www.marketscreener.com/news/immunic-inc-nasdaqcm-imux-added-to-russell-3000e-value-benchmark-ce7f5fddda8af225", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T14:13:14", "published_display": "29 Jun 2026 14:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) director receives grant of 25,370 fully vested options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPeUg5VUg5Qmc0Q0VKYk1kWktjSndvQklhRGlzNEswYTFtdDdHdUFZdjYwZHQ2S0ZkNEQ3QTRKbUhyNndBdy1xX2h5Q09sRU5sNmR2STJONnF4UUh2ODl2b3RLSWhaT2N3Ymd6Y0FJQkFDVFQ5c0VmX3dTMW4zdk5TVlREdUtpQ29yVldMUkpfZFI2VnZJaDJqWlYwTHJySTQ4eXgwQ1hveHo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUNIC (IMUX) director receives 445,000 stock options at $11.60 exercise price", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOMnYzeEk1bF9aZ04zcFd2Q3d3RzF2WVdlMFFaQXRXQ0VKRURZejlOM0d5WWFrZmtzRVJsZHU1RFdjbkdtZXNvVUM3LXBlM3VzUFRxb3ItczFtVE9SODlqbWo2X3ROTzBHSDZGVllVVWFNNTZYNGhUaXo2VTdqUUQ1MGd1eHJmU2VqaG5tMHhVTEctN0twcl9BMUJITTRCYTVZZlQxOFBjNDM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (NASDAQ: IMUX) director receives 25,370 stock options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPRWN5aTVOeHU4QzhQcmVZbU9JUDhQTjY5UXJMaVdDQ0FybUZnUjVXOGJJQWMtQXpxUHo4VndnY1U0bFUyaEl5cV9haTY4OVVwT051NnZmS2phcm1oV2pfMThmYW5xWmo1NGwwT2ZwUkw3aDJ0bDBjczRCZDVxSHRPa0NNVWctbGNmNDg4bXpDLTNFS2RtX3hzOElNYXVIR2lnb1RPdi1hYXA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUNIC (IMUX) director Barclay Phillips receives 25,370 fully vested stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQM3VnNGJmUzQ4am51OHdDTVo2eUZRaG1JUmwyQ1ItdURRU2VFWjVYRlpxU3dhMy1mNlpWMGdHcTd4c05oZV9DNWxQZjBuTjYxekhkSFo1NHZsUk5JZm5JT29zLXRNeTFRSFQwdVRTVlducHVXc3JnSFdaRlV2b25JUFlsM0JKdnNpbHE0Vl9yWkVqMVM5X3djWHNONm1zdlNfQXdIT2ZvcGQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUNIC (IMUX) President and COO receives 253,000-share stock option grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZXNwbW40UWRuQk4zNVNCQlhYUHVpNU1WejV4YWpVcHdpS0ZVZGl6M0dwZ3BEeHlScE9JV3ZHUWFZVGhxOTM3dmM3a1pZU0ZfbkRGNXpBaXBUNUVod1o1WUN3UkFEMFRqRE1RekNOWWVueGpFT2tPX29jZDBXbWU3LUIyMTBTdkllalV4TlhDNkFTaExWT1FYM1hNdXZPRTNyN2JBMWd0bmI?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Immunic, Inc. \u2013 NASDAQ:IMUX", "summary": "This article displays the \"Price to earnings forward\" financial metric for Immunic, Inc. (NASDAQ: IMUX). The content indicates \"No trades\" and \"Market closed,\" suggesting a lack of recent trading activity or data points for this specific financial ratio. The page provides a gener", "url": "https://www.tradingview.com/symbols/NASDAQ-IMUX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:39:20", "published_display": "27 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Immunic, Inc. \u2013 BOATS:IMUX", "summary": "This article provides financial information for Immunic, Inc. (IMUX), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed with no trades recorded at the time of publication. The content also mentions the various data providers for", "url": "https://www.tradingview.com/symbols/BOATS-IMUX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:40:51", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic tests Nurr1 to push beyond MS\u2019s inflammation ceiling", "summary": "Immunic Inc. is testing vidofludimus calcium, a Phase III candidate for multiple sclerosis, which combines DHODH inhibition with Nurr1 activation. This approach aims to pair targeted immune modulation with direct neuroprotective effects to slow MS progression, addressing the limi", "url": "https://www.biocentury.com/article/659787/immunic-tests-nurr1-to-push-beyond-ms-s-inflammation-ceiling", "source_name": "BioCentury", "published_at": "2026-06-27T00:40:51", "published_display": "27 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Immunic, Inc. \u2013 MUN:10V", "summary": "This article provides a financial snippet for Immunic, Inc. (MUN:10V), specifically focusing on its \"Price to book forward\" metric. The content indicates that the market for this stock is currently closed with no trades. It also lists various data providers for the financial info", "url": "https://www.tradingview.com/symbols/MUN-10V/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:39:52", "published_display": "25 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Immunic, Inc. \u2013 MUN:10V", "summary": "The article discusses the enterprise value to revenue for Immunic, Inc. (MUN:10V), traded on the Munich Stock Exchange. It appears to be a financial data snippet from a trading platform, indicating the market was closed with no trades.", "url": "https://www.tradingview.com/symbols/MUN-10V/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:11:22", "published_display": "25 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Immunic, Inc. \u2013 NASDAQ:IMUX", "summary": "This article displays the \"Enterprise value to EBITDA forward\" for Immunic, Inc. (NASDAQ:IMUX) on TradingView. It appears to be a financial data point without additional analytical text, found within the financial overview section of the company's profile on the platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-IMUX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T09:09:56", "published_display": "25 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eqs-News: Immunic to Present Additional Phase", "summary": "This article announces that Immunic will present additional Phase data, as indicated by the title \"Eqs-News: Immunic to Present Additional Phase\". However, the full content of the document is missing, making it impossible to provide further details on what data will be presented ", "url": "https://www.moomoo.com/news/flash/22557834/eqs-news-immunic-to-present-additional-phase-2-calliper-trial", "source_name": "Moomoo", "published_at": "2026-06-24T23:39:52", "published_display": "24 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Immunic, Inc. \u2013 NASDAQ:IMUX", "summary": "This article displays financial data for Immunic, Inc. (IMUX) on TradingView, specifically focusing on its enterprise value to EBIT forward ratio. The content seems to be a snapshot from a financial data platform, providing this metric for the pharmaceutical company.", "url": "https://www.tradingview.com/symbols/NASDAQ-IMUX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T19:41:35", "published_display": "24 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic Inc (FRA:10V) Stock Price & 30 Year Financial Data", "summary": "This article provides comprehensive 30-year financial data for Immunic Inc (FRA:10V), detailing growth rates for revenue, EPS, EBIT, EBITDA, and Free Cash Flow, along with price performance. It also includes key financial metrics such as Market Cap, Enterprise Value, PE Ratio, PB", "url": "https://www.gurufocus.com/stock/FRA:10V/financials", "source_name": "GuruFocus", "published_at": "2026-06-24T13:09:56", "published_display": "24 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic to Participate in Investor, Industry and Scientific Conferences in June", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immunic-participate-investor-industry-scientific-103000653.html", "source_name": "PR Newswire", "published_at": "2026-06-10T10:30:00+00:00", "published_display": "10 Jun 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic presents new vidofludimus calcium data at multiple sclerosis conference", "summary": "", "url": "https://finance.yahoo.com/m/1a380b41-3f0a-3ff9-8057-2042f00c4f69/immunic-presents-new.html", "source_name": "Proactive", "published_at": "2026-05-28T14:29:00+00:00", "published_display": "28 May 2026 14:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwJBVV95cUxOMmppSS1sU3dLa1hyTEx5TUVBVEhmcmprME9Ca1REdVhQanlGcmhIUjFWQnlIWTQ2LXUyRUx2aWUxX3g0TzQ2MlMwUWV4QVRQV1RmdzBfRXF6R0lqUl9ZRHlURUpReVIyeXlLUkxDUExqUU05dUdKTlZlSHd6cDd0Tk11ejIxaW03TXhhMWhEX3VsZS1kUWt6S0dWbUF2OWtIRVpNQkFmbjJUejhqTHNJeG1LbUp0Qk5VUTJzR1BNaEVYSFJrblRhUll1SHJPSE5KdkR6TVFlS1Q1eDFYT05zdlRJbnpPbFk2NkozUUNhT3dtaXJLM3J2LUlKTk1CVnlFY2taZ3VvWi1EYjA5NHdkcU1Lc1ktb0NKWmVoOWZIYkxwWHhrWWFWdHhNZ0hzNFc5ZnFibU04WUNPeVVmY2Z4eUJibFJ2RmI5dUNWS1AwMA?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials", "summary": "", "url": "https://finance.yahoo.com/m/13af05f7-1a6c-3a84-b5e0-555bd7424b81/immunic-names-erik-lundgren.html", "source_name": "Proactive", "published_at": "2026-05-27T13:06:00+00:00", "published_display": "27 May 2026 13:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/exclusive-immunic-appoints-former-genentech-101745260.html", "source_name": "Benzinga", "published_at": "2026-05-27T10:17:45+00:00", "published_display": "27 May 2026 10:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOTGR3N2c2N2xKdFd2Y3g2MXZyV042SUIydWVDdS15aDRSN3BaWUFEQmU2YWdXdVpkTVVfbUFrdldFd1hYblQ5SjZqc0lXTlZ6eDhTaVhOeGxMUF9GVWd6X1ZKbVBKV1djNThJN3psQV9weHd6YXU2QXpmRDAtZ3dldERtRFVsNHhiM1V3UVJPckIwazRVemJUUVRNTHZoY1hmOW54UWdaUlRDWDVKazhaRUp2M3dfWFh5MmVONkFSQ184X3JCaV9WREpVRHlhU0prb2Vidlk4NFRieV9IOTZ1UmloelozSDFrSTM4?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout", "summary": "", "url": "https://finance.yahoo.com/m/6c03c95a-4946-3c70-ae8e-860ac7dd3477/immunic-appoints-biogen%2C.html", "source_name": "Proactive", "published_at": "2026-05-19T13:33:00+00:00", "published_display": "19 May 2026 13:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immunic-appoints-seasoned-biopharmaceutical-executive-103000434.html", "source_name": "PR Newswire", "published_at": "2026-05-19T10:30:00+00:00", "published_display": "19 May 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunic-nasdaq-imux-good-position-143141130.html", "source_name": "Simply Wall St.", "published_at": "2026-05-17T14:31:41+00:00", "published_display": "17 May 2026 14:31", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic stock (US45256V1061): Q1 earnings and Phase 3 trial preparations", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOSFhHNE56ZVEzVjB4bUZ2NW8ycXFJVjZ2eUh5d3ZMM3BJaGJlWTFrbjItUndWaUZoVjBHb2tWZmxlbXlyaC1fN0lkZXFLNXhiSmJVanhyRHo5aDVuczJKNkdPd1otc3hGYTJ6WUt0eUVLNkVIaUFHOXZxVXpEa0tfcDB3YVZlNzIzQWlPOGxGQ2cteDlsMWc1SjJSVUhabnJVakFnb0VPQU9oYVpDeVg2SXU2QWN2STVxZXVsb0NjeDY3UFVpRjVB?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQT19UUTgzYU1fUmdzSDNmaVgwZVFKbWpWa3ZUdnFrWGdNcjhqcUFnWVJyM19QNDFvTGFRcS1QTlNhMUVWVWhDa0tSTG9PN0dYYVVWSnNBYWpOY3FfWlQ5bWNhNENMVDZVc1VJVk52SzYzOG1jQTBpWDZaeWhsTngwYW1oVGNYSEY4YzhQWlVscVFad2VvdkJRejZkVGZyVnpqR1FsYld4N0c3V0xwUjJIblRDWUJ4MkxUeDJoR1ViS1BvQlVhaWZJSkxRQXo2eHF1SktOeW5ROA?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic (IMUX) Q1 2026 Earnings: EPS N/A, Revenue N/A -- Is the", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQUWtCS0xxcExaM2wxRmJQOGtMMkR3S1EzMTdMdlBpaDUwOUQycFFlWnA3NldzQmVZcnQ4U3hxQUxONTdNVDQ4c2tEWEstS1VQcl9iSDV3bHNONVFhbTBkcXAyUEZ2cWV5bDl4Z1cxaHVtM2Vjd0JVd2Y0N1pKcWEtV1B5NUdISWx4Y1NpQmNYZmZOUzFRWnBOREM3c09zdXVRNUlKUXpDTUFJaFhkSTdZMVhiV2pyUWNNZEVZam0xeFlaaWhGUTZwaHlWaXZSNnJkS1JQOA?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic Releases Q1 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE1rZ3dkR2d2a2VNX3NtT19OTUJLOHRmUWhINHRyazdpdFZlVzRfMjNSalJFU1RoVTVxejZiM3g2YkVQWTE3TGhybUdWVzJnNnpWdmV1d3U1YkpMWE9KNFNYNkVIVUgyak5CdVBYNjRGdmVhM25ncy1XQ1RGVWjSAXxBVV95cUxNa2d3ZEdndmtlTV9zbU9fTk1CSzh0ZlFoSDR0cms3aXRWZVc0XzIzUmpSRVNUaFU1cXo2YjN4NmJFUFkxN0xocm1HVlcyZzZ6VnZldXd1NWJKTFhPSjRTWDZFSFVIMmpOQnVQWDY0RnZlYTNuZ3MtV0NURlVo?oc=5", "source_name": "AlphaStreet", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic, Inc. Announces 1-for-10 Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQSTFxLXBTOWx0eGE0b3NKUzVfQXlIYjVSMWN1b2RNVGpRYWYxWXBUU2FsZW5BemRyc0xWYi1HYXpMVURHSm42TUpRdGNOZTBHUTBOMXY5c2JPYS1zeEM4RHlvY0t6ckR3QnhMRFc4LXVCbkZyYW1NYkhKS1Mwc1JzdnJBMlNKTC1zUHY2a0l0MFQ1UElfckFHUVFfYzNWUzdXb0pzd1RmZw?oc=5", "source_name": "TradingView", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunic shareholders approve 1-for-10 reverse stock split, effective April 27", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNYWhjeDczcEtkTHlYdGdXVUdiRmQtUll2ZmdvbkVuc293LXJ0QlRxMWRweXkyaE4zcWs0ZlZJSXdPNDRHZ1ZPYVkxMTU5Z2VpU3VwaUpkNW5BVjJPVUlHRElRZklKQWZRSGNKZzVjTnczYlRpNjJsTm95Um9qMU1HWHdZMGotdUcwMjFrTExXMkdhTnVmdmk0MG1uMWRYN1JnR0ZWSzY2TUVOak41aS1NLUtYS3E2bGF1eTdWZ2UyU0w5WkloMDFnRk9n?oc=5", "source_name": "Investing.com", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Extended European Patent Protection for Vidofludimus Calcium Reshape Immunic\u2019s (IMUX) Long-Term Value Proposition?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-14T07:00:00+00:00", "published_display": "14 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 104, "total_relevant": 68, "sentiment_summary": {"positive": 6, "negative": 1, "neutral": 61, "score": 51, "total": 68, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 23.1, "count": 42}, {"event": "earnings", "label": "Earnings", "weight": 8.66, "count": 18}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 14.77, "latest_week": "2026-07-10", "one_week_move": -0.2, "four_week_move": 6.6, "twelve_week_move": 47.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.616972, "market_dynamics_buy_signal": false, "relative_strength": 33.98602, "fair_value_gap": 27.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 50.5959, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.2% over one week, +6.6% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 50, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 16}, {"label": "TradingView", "count": 10}, {"label": "Market source", "count": 6}, {"label": "PR Newswire", "count": 5}, {"label": "Proactive", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "ad-hoc-news.de", "count": 2}, {"label": "Finviz", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 59}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 42}, {"label": "Earnings", "count": 18}, {"label": "Regulatory and legal", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "59", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.2% over one week, +6.6% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "abrdn discloses 6.05% Immunic (IMUX) stake held for clients"}], "updated_at": "2026-07-18T01:14:56.159599+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}